OncoHost, a technology company focused on transforming the approach to precision medicine for improved patient outcomes, announced on Thursday that it has received 'Proteomics Innovation of the Year' in the fifth annual BioTech Breakthrough Awards.

The awards aim to recognise breakthrough life sciences and biotechnology innovation around the world.

OncoHost's PROphet platform is a plasma-based tool that leverages proteomic pattern recognition, bioinformatics, and AI to support and enhance clinical decision-making for oncologists. The platform's initial offering, PROphetNSCLC, is the first liquid biopsy proteomics test designed to guide immunotherapy treatment choices in late-stage non-small cell lung cancer (NSCLC). Available in the United States, PROphetNSCLC provides clinicians with actionable insights based on a single pre-treatment blood sample that captures dynamic biological processes in real time, enabling more personalised and effective therapeutic strategies.